Département de Physique, de génie Physique et d'optique et Centre de Recherche sur le Cancer, Université Laval, Quebec, QC, Canada.
Département de radio-oncologie et Axe Oncologie du CRCHU de Québec, CHU de Québec - Université Laval, Quebec, QC, Canada.
Phys Med Biol. 2021 Apr 16;66(8). doi: 10.1088/1361-6560/abf1bd.
This study introduces the HYPERSCINT research platform (HYPERSCINT-RP100, Medscint Inc., Quebec, Canada), the first commercially available scintillation dosimetry platform capable of multi-point dosimetry through the hyperspectral approach. Optic and dosimetric performances of the system were investigated through comparison with another commercially available solution, the Ocean Optics QE65Pro spectrometer. The optical characterization was accomplished by measuring the linearity of the signal as a function of integration time, photon detection efficiency and spectral resolution for both systems under the same conditions. Dosimetric performances were then evaluated with a 3-point plastic scintillator detector (mPSD) in terms of signal to noise ratio (SNR) and signal to background ratio (SBR) associated with each scintillator. The latter were subsequently compared with those found in the literature for the Exradin W1, a single-point plastic scintillator detector. Finally, various beam measurements were realized with the HYPERSCINT platform to evaluate its ability to perform clinical photon beam dosimetry. Both systems were found to be comparable in terms of linearity of the signal as a function of the intensity. Although the QE65Pro possesses a higher spectral resolution, the detection efficiency of the HYPERSCINT is up to 1000 time greater. Dosimetric measurements shows that the latter also offers a better SNR and SBR, surpassing even the SNR of the Exradin W1 single-point PSD. While doses ranging from 1 to 600 cGy were accurately measured within 2.1% of the predicted dose using the HYPERSCINT platform coupled to the mPSD, the Ocean optics spectrometer shows discrepancies up to 86% under 50cGy. Similarly, depth dose, full width at half maximum region of the beam profile and output factors were all accurately measured within 2.3% of the predicted dose using the HYPERSCINT platform and exhibit an average difference of 0.5%, 1.6% and 0.6%, respectively.
本研究介绍了 HYPERSCINT 研究平台（HYPERSCINT-RP100，Medscint Inc.，魁北克，加拿大），这是第一个可通过超光谱方法进行多点剂量测量的商业可用闪烁体剂量测量平台。通过与另一个商业上可用的解决方案——Ocean Optics QE65Pro 光谱仪进行比较，研究了该系统的光学和剂量学性能。在相同条件下，通过测量两个系统的信号积分时间、光子探测效率和光谱分辨率的线性度，完成了光学特性的表征。然后，使用 3 点塑料闪烁体探测器（mPSD），根据每个闪烁体的信噪比（SNR）和信号与背景比（SBR）来评估剂量学性能。随后，将这些性能与文献中 Exradin W1 单点塑料闪烁体探测器的结果进行了比较。最后，使用 HYPERSCINT 平台进行了各种光束测量，以评估其进行临床光子束剂量测量的能力。在信号强度的线性度方面，两个系统的性能相当。尽管 QE65Pro 具有更高的光谱分辨率，但 HYPERSCINT 的探测效率高达其 1000 倍。剂量学测量表明，后者还提供了更好的 SNR 和 SBR，甚至超过了 Exradin W1 单点 PSD 的 SNR。使用与 mPSD 耦合的 HYPERSCINT 平台，可在 2.1%的预测剂量内准确测量 1 至 600 cGy 的剂量，而 Ocean optics 光谱仪在 50 cGy 时的误差高达 86%。同样，使用 HYPERSCINT 平台，深度剂量、光束剖面的半高全宽区域和输出因子都可在 2.3%的预测剂量内准确测量，平均差异分别为 0.5%、1.6%和 0.6%。
